Everita Capital buys majority stake in Prague clinical trial centre Clintrial
What's the deal? Czech growth investor Everita CapitalDealroom has a profile for this one. Try Dealroom → has acquired a majority stake in ClintrialDealroom has a profile for this one. Try Dealroom →, a Prague-based clinical trial centre. Founders Dr Zdeněk Šolle and his wife Barbora remain invested in the business.
What does Clintrial do? Established in 2005, it began running clinical trials in psychiatry before expanding into neurology and diabetology. It now also covers obesity, gastroenterology, cardiology, haematology, pneumology, phlebology, and dermatology.
The track record: Clintrial has enrolled over 1,000 patients and contributed to more than 100 Phase II and III clinical trials.
What's the endgame? With Everita, Clintrial plans to expand capacity, enter new therapeutic areas, and build a broader network of clients, physicians, and healthcare providers. Everita focuses on growth investments in Central European SMEs.
Key hire: The company is strengthening its leadership with Tomas Brezina, who brings over 25 years in pharmaceuticals and biotech, including eight years as chief executive officer of AmgenDealroom has a profile for this one. Try Dealroom → in the Czech Republic.
Who's backing it? The deal brought new investors into the Everita FundDealroom has a profile for this one. Try Dealroom →, including RenteaDealroom has a profile for this one. Try Dealroom →, and offered a co-investment opportunity to existing limited partners.
The signal: The acquisition points to growing investor interest in Central Europe's clinical research infrastructure, as specialist trial centres seek capital to scale across new therapeutic areas.
Image credit: NavyMedicine
